Sally M.
- Country
- Germany
- Department
- Pädiatrische Onkologie und Hämatologie
Research Overview
- Reduced‑intensity post‑induction chemotherapy plus blinatumomab versus standard post‑induction therapy in pediatric standard‑risk B‑ALL (AIEOP‑BFM ALL 2025)
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Bortezomib, Blinatumomab, and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 80 of 181 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of acute lymphoblastic leukemia (ALL), with particular emphasis on pediatric and adolescent cases. Their research focuses on developing innovative therapeutic approaches for different risk categories of ALL.
- Philadelphia chromosome-positive ALL
- Early high-risk B-cell ALL
- Intermediate risk B-cell ALL
The investigator's work encompasses comprehensive treatment protocols combining chemotherapy and targeted therapies.
Personalized Medicine
Their expertise extends to developing risk-stratified treatment approaches for leukemia patients, incorporating genetic factors and treatment response assessments to optimize therapeutic outcomes.
- Response-adapted therapy
- Genetic profiling in ALL
- Risk-based treatment protocols
The investigator integrates molecular diagnostics with therapeutic decision-making to enhance treatment efficacy.
Immunotherapy Research
The investigator explores innovative immunotherapeutic approaches in treating acute lymphoblastic leukemia, including the application of targeted biological agents.
- Targeted immunotherapy
- Combination treatment strategies
- Novel therapeutic protocols
Their work involves evaluating the effectiveness of immunotherapy in various ALL risk groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.